C. Sahin, M. C. Terek, A. Ozsaran, Y. Dikmen, B. Karabulut
{"title":"LIPOSOMAL DOXORUBICIN-RELATED PALMAR-PLANTAR ERTHRODYSESTHESIA (HAND-AND FOOT SYNDROME): REPORT OF A CASE","authors":"C. Sahin, M. C. Terek, A. Ozsaran, Y. Dikmen, B. Karabulut","doi":"10.5505/TJOD.2011.87059","DOIUrl":null,"url":null,"abstract":"SUMMARY Palmar-plantar erthrodyesthes›a (PPE) (hand and foot syndrome) is a dermatological toxic reaction related to some chemotherapeutic agents. Liposomal doxorubicin is the long-acting formula of doxorubisin and it causes PPE in 50% of the patients when used with the dosage of 50 mg/m2. The disease causes burning sensation in the hands and feet and then shows progression by edema and erythema. After the disease is estbalished the treatment consists of lowering the drug dosage, prolonging the dose intervals or discontinuing the drug as well as using topical agents.","PeriodicalId":174635,"journal":{"name":"Journal of Turkish Society of Obstetric and Gynecology","volume":"1 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Turkish Society of Obstetric and Gynecology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5505/TJOD.2011.87059","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
SUMMARY Palmar-plantar erthrodyesthes›a (PPE) (hand and foot syndrome) is a dermatological toxic reaction related to some chemotherapeutic agents. Liposomal doxorubicin is the long-acting formula of doxorubisin and it causes PPE in 50% of the patients when used with the dosage of 50 mg/m2. The disease causes burning sensation in the hands and feet and then shows progression by edema and erythema. After the disease is estbalished the treatment consists of lowering the drug dosage, prolonging the dose intervals or discontinuing the drug as well as using topical agents.